ID   PK3CD_HUMAN             Reviewed;        1044 AA.
AC   O00329; A6NCG0; G1FFP1; O15445; Q5SR49;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 2.
DT   10-MAY-2017, entry version 168.
DE   RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;
DE            Short=PI3-kinase subunit delta;
DE            Short=PI3K-delta;
DE            Short=PI3Kdelta;
DE            Short=PtdIns-3-kinase subunit delta;
DE            EC=2.7.1.153;
DE   AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta;
DE            Short=PtdIns-3-kinase subunit p110-delta;
DE            Short=p110delta;
GN   Name=PIK3CD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9113989; DOI=10.1073/pnas.94.9.4330;
RA   Vanhaesebroeck B.A.M., Welham M.J., Kotani K., Stein R., Warne P.H.,
RA   Zvelebil M.J., Higashi K., Volinia S., Downward J., Waterfield M.D.;
RT   "P110delta, a novel phosphoinositide 3-kinase in leukocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:4330-4335(1997).
RN   [2]
RP   SEQUENCE REVISION TO 675.
RA   Vanhaesebroeck B.A.M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9235916; DOI=10.1074/jbc.272.31.19236;
RA   Chantry D., Vojtek A., Kashishian A., Holtzman D.A., Wood C.,
RA   Gray P.W., Cooper J.A., Hoekstra M.F.;
RT   "p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit
RT   that associates with p85 and is expressed predominantly in
RT   leukocytes.";
RL   J. Biol. Chem. 272:19236-19241(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBUNIT, INTERACTION
RP   WITH HRAS, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=22020336; DOI=10.1038/onc.2011.492;
RA   Fransson S., Uv A., Eriksson H., Andersson M.K., Wettergren Y.,
RA   Bergo M., Ejeskar K.;
RT   "p37delta is a new isoform of PI3K p110delta that increases cell
RT   proliferation and is overexpressed in tumors.";
RL   Oncogene 31:3277-3286(2012).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Jou S.-T., Chien Y.-H., Yang Y.-H., Shyur S.-D., Chou C.-C.,
RA   Chiang B.-L.;
RT   "Variations in the human phosphoinositide-3-kinase p110 gene in
RT   children with primary B-cell immunodeficiency of unknown etiology.";
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 1031-1040, PHOSPHORYLATION AT SER-1039, AND
RP   MUTAGENESIS OF ARG-894 AND SER-1039.
RX   PubMed=10064595; DOI=10.1093/emboj/18.5.1292;
RA   Vanhaesebroeck B., Higashi K., Raven C., Welham M., Anderson S.,
RA   Brennan P., Ward S.G., Waterfield M.D.;
RT   "Autophosphorylation of p110 delta phosphoinositide 3-kinase: a new
RT   paradigm for the regulation of lipid kinases in vitro and in vivo.";
RL   EMBO J. 18:1292-1302(1999).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-524 AND SER-1039, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   FUNCTION IN T-CELLS, AND ENZYME REGULATION.
RX   PubMed=20081091; DOI=10.1182/blood-2009-07-232330;
RA   Soond D.R., Bjorgo E., Moltu K., Dale V.Q., Patton D.T.,
RA   Torgersen K.M., Galleway F., Twomey B., Clark J., Gaston J.S.H.,
RA   Tasken K., Bunyard P., Okkenhaug K.;
RT   "PI3K p110delta regulates T-cell cytokine production during primary
RT   and secondary immune responses in mice and humans.";
RL   Blood 115:2203-2213(2010).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=17290298; DOI=10.1038/nri2036;
RA   Rommel C., Camps M., Ji H.;
RT   "PI3K delta and PI3K gamma: partners in crime in inflammation in
RT   rheumatoid arthritis and beyond?";
RL   Nat. Rev. Immunol. 7:191-201(2007).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=20940048; DOI=10.1016/j.cellsig.2010.10.002;
RA   Fung-Leung W.-P.;
RT   "Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling
RT   and function.";
RL   Cell. Signal. 23:603-608(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1039, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   VARIANT APDS LYS-1021, AND CHARACTERIZATION OF VARIANT APDS LYS-1021.
RX   PubMed=24136356; DOI=10.1126/science.1243292;
RA   Angulo I., Vadas O., Garcon F., Banham-Hall E., Plagnol V.,
RA   Leahy T.R., Baxendale H., Coulter T., Curtis J., Wu C.,
RA   Blake-Palmer K., Perisic O., Smyth D., Maes M., Fiddler C., Juss J.,
RA   Cilliers D., Markelj G., Chandra A., Farmer G., Kielkowska A.,
RA   Clark J., Kracker S., Debre M., Picard C., Pellier I., Jabado N.,
RA   Morris J.A., Barcenas-Morales G., Fischer A., Stephens L., Hawkins P.,
RA   Barrett J.C., Abinun M., Clatworthy M., Durandy A., Doffinger R.,
RA   Chilvers E.R., Cant A.J., Kumararatne D., Okkenhaug K., Williams R.L.,
RA   Condliffe A., Nejentsev S.;
RT   "Phosphoinositide 3-kinase delta gene mutation predisposes to
RT   respiratory infection and airway damage.";
RL   Science 342:866-871(2013).
CC   -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) that phosphorylates
CC       PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate
CC       phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key
CC       role by recruiting PH domain-containing proteins to the membrane,
CC       including AKT1 and PDPK1, activating signaling cascades involved
CC       in cell growth, survival, proliferation, motility and morphology.
CC       Mediates immune responses. Plays a role in B-cell development,
CC       proliferation, migration, and function. Required for B-cell
CC       receptor (BCR) signaling. Mediates B-cell proliferation response
CC       to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine
CC       production in response to TLR4 and TLR9. Required for antibody
CC       class switch mediated by TLR9. Involved in the antigen
CC       presentation function of B-cells. Involved in B-cell chemotaxis in
CC       response to CXCL13 and sphingosine 1-phosphate (S1P). Required for
CC       proliferation, signaling and cytokine production of naive,
CC       effector and memory T-cells. Required for T-cell receptor (TCR)
CC       signaling. Mediates TCR signaling events at the immune synapse.
CC       Activation by TCR leads to antigen-dependent memory T-cell
CC       migration and retention to antigenic tissues. Together with PIK3CG
CC       participates in T-cell development. Contributes to T-helper cell
CC       expansion and differentiation. Required for T-cell migration
CC       mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and
CC       antigen dependent recruitment of T-cells. Together with PIK3CG is
CC       involved in natural killer (NK) cell development and migration
CC       towards the sites of inflammation. Participates in NK cell
CC       receptor activation. Have a role in NK cell maturation and
CC       cytokine production. Together with PIK3CG is involved in
CC       neutrophil chemotaxis and extravasation. Together with PIK3CG
CC       participates in neutrophil respiratory burst. Have important roles
CC       in mast-cell development and mast cell mediated allergic response.
CC       Involved in stem cell factor (SCF)-mediated proliferation,
CC       adhesion and migration. Required for allergen-IgE-induced
CC       degranulation and cytokine release. The lipid kinase activity is
CC       required for its biological function. Isoform 2 may be involved in
CC       stabilizing total RAS levels, resulting in increased ERK
CC       phosphorylation and increased PI3K activity.
CC       {ECO:0000269|PubMed:20081091, ECO:0000269|PubMed:22020336}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-
CC       trisphosphate.
CC   -!- ENZYME REGULATION: Activated by growth factors and cytokine
CC       receptors through a tyrosine-kinase-dependent mechanism. Activated
CC       by RAS. IC87114 inhibits lipid kinase activity and is selective in
CC       cells at doses up to 5-10 uM. IC87114 blocks T-cell receptor
CC       signaling in naive and memory T-cells and reduces cytokine
CC       production by memory T-cells. {ECO:0000269|PubMed:20081091}.
CC   -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate
CC       biosynthesis.
CC   -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CD and a p85
CC       regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interacts with ERAS
CC       (By similarity). Interacts with HRAS. {ECO:0000250,
CC       ECO:0000269|PubMed:22020336}.
CC   -!- INTERACTION:
CC       P01112:HRAS; NbExp=2; IntAct=EBI-718309, EBI-350145;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22020336}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=p110-delta;
CC         IsoId=O00329-1; Sequence=Displayed;
CC       Name=2; Synonyms=p37-delta;
CC         IsoId=O00329-2; Sequence=VSP_044409, VSP_044410;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is expressed in normal thymus, lung
CC       and spleen tissues, and is detected at low levels in normal
CC       lysates from colon and ovarian biopsies, at elevated levels in
CC       lysates from colorectal tumors and is abundantly expressed in some
CC       ovarian tumors (at protein level). Both isoform 1 and isoform 2
CC       are widely expressed. Isoform 1 is expressed predominantly in
CC       leukocytes. {ECO:0000269|PubMed:22020336}.
CC   -!- PTM: Autophosphorylation on Ser-1039 results in the almost
CC       complete inactivation of the lipid kinase activity.
CC       {ECO:0000269|PubMed:10064595}.
CC   -!- DISEASE: Activated PI3K-delta syndrome (APDS) [MIM:615513]: A
CC       disorder characterized by recurrent respiratory infections,
CC       progressive airway damage, lymphopenia, increased circulating
CC       transitional B cells, increased immunoglobulin M, reduced
CC       immunoglobulin G2 levels in serum, and impaired vaccine responses.
CC       {ECO:0000269|PubMed:24136356}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: IC87114 inhibitor reduces passive cutaneous
CC       anaphylaxis, attenuates allergic airway inflammation and
CC       hyperresponsiveness and allergen induced rhinitis response.
CC       Inhibitors may have therapeutic potential for the treatment of
CC       immune system-mediated diseases such as auto-immune diseases,
CC       inflammation and allergy (PubMed:20940048; PubMed:17290298).
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00877, ECO:0000255|PROSITE-
CC       ProRule:PRU00879, ECO:0000255|PROSITE-ProRule:PRU00880}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PIK3CDID46261ch1p36.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y10055; CAA71149.2; -; mRNA.
DR   EMBL; U86453; AAC25677.1; -; mRNA.
DR   EMBL; JN190435; AEK81610.1; -; mRNA.
DR   EMBL; DQ263594; ABB83814.1; -; mRNA.
DR   EMBL; AL691449; CAI15703.1; -; Genomic_DNA.
DR   EMBL; BC132919; AAI32920.1; -; mRNA.
DR   EMBL; BC132921; AAI32922.1; -; mRNA.
DR   CCDS; CCDS104.1; -. [O00329-1]
DR   RefSeq; NP_005017.3; NM_005026.3. [O00329-1]
DR   RefSeq; XP_006710750.1; XM_006710687.2. [O00329-1]
DR   RefSeq; XP_006710752.1; XM_006710689.2. [O00329-1]
DR   UniGene; Hs.518451; -.
DR   PDB; 5DXU; X-ray; 2.64 A; A=2-1044.
DR   PDB; 5M6U; X-ray; 2.85 A; A=17-1027.
DR   PDB; 5T8F; X-ray; 2.91 A; A=17-1031.
DR   PDB; 5UBT; X-ray; 2.83 A; A=17-1029.
DR   PDBsum; 5DXU; -.
DR   PDBsum; 5M6U; -.
DR   PDBsum; 5T8F; -.
DR   PDBsum; 5UBT; -.
DR   ProteinModelPortal; O00329; -.
DR   SMR; O00329; -.
DR   BioGrid; 111311; 10.
DR   IntAct; O00329; 10.
DR   STRING; 9606.ENSP00000366563; -.
DR   BindingDB; O00329; -.
DR   ChEMBL; CHEMBL3130; -.
DR   DrugBank; DB06831; 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB05241; XL765.
DR   GuidetoPHARMACOLOGY; 2155; -.
DR   SwissLipids; SLP:000000908; -.
DR   iPTMnet; O00329; -.
DR   PhosphoSitePlus; O00329; -.
DR   BioMuta; PIK3CD; -.
DR   EPD; O00329; -.
DR   MaxQB; O00329; -.
DR   PaxDb; O00329; -.
DR   PeptideAtlas; O00329; -.
DR   PRIDE; O00329; -.
DR   DNASU; 5293; -.
DR   Ensembl; ENST00000377346; ENSP00000366563; ENSG00000171608. [O00329-1]
DR   GeneID; 5293; -.
DR   KEGG; hsa:5293; -.
DR   UCSC; uc001aqb.5; human. [O00329-1]
DR   CTD; 5293; -.
DR   DisGeNET; 5293; -.
DR   GeneCards; PIK3CD; -.
DR   HGNC; HGNC:8977; PIK3CD.
DR   HPA; CAB015420; -.
DR   HPA; HPA044953; -.
DR   MalaCards; PIK3CD; -.
DR   MIM; 602839; gene.
DR   MIM; 615513; phenotype.
DR   neXtProt; NX_O00329; -.
DR   OpenTargets; ENSG00000171608; -.
DR   Orphanet; 397596; Activated PIK3-delta syndrome.
DR   PharmGKB; PA33310; -.
DR   eggNOG; KOG0904; Eukaryota.
DR   eggNOG; COG5032; LUCA.
DR   GeneTree; ENSGT00760000119110; -.
DR   HOGENOM; HOG000252911; -.
DR   HOVERGEN; HBG052721; -.
DR   InParanoid; O00329; -.
DR   KO; K00922; -.
DR   PhylomeDB; O00329; -.
DR   TreeFam; TF102031; -.
DR   BioCyc; MetaCyc:ENSG00000171608-MONOMER; -.
DR   BRENDA; 2.7.1.137; 2681.
DR   BRENDA; 2.7.1.153; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; O00329; -.
DR   SIGNOR; O00329; -.
DR   UniPathway; UPA00220; -.
DR   ChiTaRS; PIK3CD; human.
DR   GeneWiki; P110%CE%B4; -.
DR   GenomeRNAi; 5293; -.
DR   PRO; PR:O00329; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000171608; -.
DR   CleanEx; HS_PIK3CD; -.
DR   ExpressionAtlas; O00329; baseline and differential.
DR   Genevisible; O00329; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IBA:GO_Central.
DR   GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IDA:MGI.
DR   GO; GO:0035004; F:phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0002250; P:adaptive immune response; TAS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0035754; P:B cell chemotaxis; TAS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0001816; P:cytokine production; TAS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0002551; P:mast cell chemotaxis; TAS:UniProtKB.
DR   GO; GO:0043303; P:mast cell degranulation; TAS:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030101; P:natural killer cell activation; TAS:UniProtKB.
DR   GO; GO:0035747; P:natural killer cell chemotaxis; TAS:UniProtKB.
DR   GO; GO:0001779; P:natural killer cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030593; P:neutrophil chemotaxis; TAS:UniProtKB.
DR   GO; GO:0072672; P:neutrophil extravasation; TAS:UniProtKB.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IMP:CAFA.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0016310; P:phosphorylation; IDA:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:CACAO.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:CACAO.
DR   GO; GO:0033031; P:positive regulation of neutrophil apoptotic process; IMP:CAFA.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0002679; P:respiratory burst involved in defense response; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0042110; P:T cell activation; TAS:UniProtKB.
DR   GO; GO:0010818; P:T cell chemotaxis; TAS:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; TAS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:UniProtKB.
DR   Gene3D; 1.10.1070.11; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003113; PI3K_adapt-bd_dom.
DR   InterPro; IPR002420; PI3K_C2_dom.
DR   InterPro; IPR000341; PI3K_Ras-bd_dom.
DR   InterPro; IPR015433; PI_Kinase.
DR   InterPro; IPR001263; PInositide-3_kin_accessory_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   PANTHER; PTHR10048; PTHR10048; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF00792; PI3K_C2; 1.
DR   Pfam; PF02192; PI3K_p85B; 1.
DR   Pfam; PF00794; PI3K_rbd; 1.
DR   Pfam; PF00613; PI3Ka; 1.
DR   SMART; SM00142; PI3K_C2; 1.
DR   SMART; SM00143; PI3K_p85B; 1.
DR   SMART; SM00144; PI3K_rbd; 1.
DR   SMART; SM00145; PI3Ka; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51544; PI3K_ABD; 1.
DR   PROSITE; PS51547; PI3K_C2; 1.
DR   PROSITE; PS51546; PI3K_RBD; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; ATP-binding;
KW   Chemotaxis; Complete proteome; Cytoplasm; Differentiation;
KW   Direct protein sequencing; Disease mutation; Immunity;
KW   Inflammatory response; Innate immunity; Kinase; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Transferase.
FT   CHAIN         1   1044       Phosphatidylinositol 4,5-bisphosphate 3-
FT                                kinase catalytic subunit delta isoform.
FT                                /FTId=PRO_0000088790.
FT   DOMAIN       16    105       PI3K-ABD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00877}.
FT   DOMAIN      187    278       PI3K-RBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00879}.
FT   DOMAIN      319    476       C2 PI3K-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00880}.
FT   DOMAIN      497    674       PIK helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00878}.
FT   DOMAIN      774   1041       PI3K/PI4K. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00269}.
FT   MOD_RES     315    315       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BTI9}.
FT   MOD_RES     524    524       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES    1039   1039       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10064595}.
FT   VAR_SEQ     201    300       ESFTFQVSTKDVPLALMACALRKKATVFRQPLVEQPEDYTL
FT                                QVNGRHEYLYGSYPLCQFQYICSCLHSGLTPHLTMVHSSSI
FT                                LAMRDEQSNPAPQVQKPR -> VSPCVACGIQAALSMGSTS
FT                                SVKLLSHPQAPLPQWHQMVFARCLCMCGAQLNVPPGELHLP
FT                                GVHQGRAAGADGLCPAEEGHSVPAAAGGAAGRLHAAGERQ
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:22020336}.
FT                                /FTId=VSP_044409.
FT   VAR_SEQ     302   1044       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:22020336}.
FT                                /FTId=VSP_044410.
FT   VARIANT    1021   1021       E -> K (in APDS; results in gain of
FT                                function causing enhanced membrane
FT                                association and kinase activity;
FT                                dbSNP:rs397518423).
FT                                {ECO:0000269|PubMed:24136356}.
FT                                /FTId=VAR_070918.
FT   MUTAGEN     894    894       R->P: Abolishes lipid and protein kinase
FT                                activities.
FT                                {ECO:0000269|PubMed:10064595}.
FT   MUTAGEN    1039   1039       S->A: Abolishes autophosphorylation, no
FT                                effect on lipid kinase activity.
FT                                {ECO:0000269|PubMed:10064595}.
FT   MUTAGEN    1039   1039       S->D,E: Abolishes autophosphorylation,
FT                                reduced lipid kinase activity.
FT                                {ECO:0000269|PubMed:10064595}.
FT   CONFLICT    253    253       S -> N (in Ref. 3; AAC25677).
FT                                {ECO:0000305}.
FT   STRAND       19     25       {ECO:0000244|PDB:5DXU}.
FT   STRAND       31     37       {ECO:0000244|PDB:5DXU}.
FT   HELIX        42     53       {ECO:0000244|PDB:5DXU}.
FT   HELIX        59     61       {ECO:0000244|PDB:5DXU}.
FT   HELIX        65     67       {ECO:0000244|PDB:5DXU}.
FT   STRAND       68     74       {ECO:0000244|PDB:5DXU}.
FT   STRAND       79     82       {ECO:0000244|PDB:5DXU}.
FT   HELIX        89     92       {ECO:0000244|PDB:5DXU}.
FT   STRAND       94    104       {ECO:0000244|PDB:5DXU}.
FT   HELIX       108    121       {ECO:0000244|PDB:5DXU}.
FT   HELIX       126    130       {ECO:0000244|PDB:5DXU}.
FT   HELIX       134    156       {ECO:0000244|PDB:5DXU}.
FT   HELIX       159    166       {ECO:0000244|PDB:5DXU}.
FT   STRAND      192    196       {ECO:0000244|PDB:5DXU}.
FT   STRAND      203    205       {ECO:0000244|PDB:5DXU}.
FT   HELIX       213    221       {ECO:0000244|PDB:5DXU}.
FT   HELIX       236    238       {ECO:0000244|PDB:5DXU}.
FT   STRAND      239    243       {ECO:0000244|PDB:5DXU}.
FT   STRAND      248    250       {ECO:0000244|PDB:5DXU}.
FT   STRAND      252    254       {ECO:0000244|PDB:5UBT}.
FT   HELIX       256    258       {ECO:0000244|PDB:5DXU}.
FT   HELIX       260    268       {ECO:0000244|PDB:5DXU}.
FT   STRAND      273    278       {ECO:0000244|PDB:5DXU}.
FT   HELIX       279    286       {ECO:0000244|PDB:5DXU}.
FT   STRAND      321    332       {ECO:0000244|PDB:5DXU}.
FT   STRAND      339    349       {ECO:0000244|PDB:5DXU}.
FT   STRAND      352    355       {ECO:0000244|PDB:5DXU}.
FT   STRAND      370    380       {ECO:0000244|PDB:5DXU}.
FT   TURN        381    383       {ECO:0000244|PDB:5DXU}.
FT   STRAND      389    397       {ECO:0000244|PDB:5DXU}.
FT   STRAND      416    426       {ECO:0000244|PDB:5DXU}.
FT   STRAND      430    432       {ECO:0000244|PDB:5DXU}.
FT   STRAND      435    440       {ECO:0000244|PDB:5DXU}.
FT   TURN        465    467       {ECO:0000244|PDB:5DXU}.
FT   STRAND      470    475       {ECO:0000244|PDB:5DXU}.
FT   STRAND      479    481       {ECO:0000244|PDB:5UBT}.
FT   HELIX       488    491       {ECO:0000244|PDB:5DXU}.
FT   TURN        492    495       {ECO:0000244|PDB:5DXU}.
FT   HELIX       506    515       {ECO:0000244|PDB:5DXU}.
FT   STRAND      517    519       {ECO:0000244|PDB:5M6U}.
FT   HELIX       525    533       {ECO:0000244|PDB:5DXU}.
FT   HELIX       535    541       {ECO:0000244|PDB:5DXU}.
FT   HELIX       543    545       {ECO:0000244|PDB:5DXU}.
FT   HELIX       546    552       {ECO:0000244|PDB:5DXU}.
FT   HELIX       558    569       {ECO:0000244|PDB:5DXU}.
FT   HELIX       576    582       {ECO:0000244|PDB:5DXU}.
FT   HELIX       590    600       {ECO:0000244|PDB:5DXU}.
FT   HELIX       605    610       {ECO:0000244|PDB:5DXU}.
FT   HELIX       612    618       {ECO:0000244|PDB:5DXU}.
FT   HELIX       619    621       {ECO:0000244|PDB:5DXU}.
FT   STRAND      623    626       {ECO:0000244|PDB:5DXU}.
FT   HELIX       628    639       {ECO:0000244|PDB:5DXU}.
FT   HELIX       641    652       {ECO:0000244|PDB:5DXU}.
FT   TURN        653    656       {ECO:0000244|PDB:5DXU}.
FT   HELIX       658    673       {ECO:0000244|PDB:5DXU}.
FT   HELIX       676    705       {ECO:0000244|PDB:5DXU}.
FT   HELIX       708    720       {ECO:0000244|PDB:5DXU}.
FT   HELIX       722    728       {ECO:0000244|PDB:5DXU}.
FT   STRAND      729    732       {ECO:0000244|PDB:5DXU}.
FT   STRAND      739    741       {ECO:0000244|PDB:5DXU}.
FT   TURN        746    748       {ECO:0000244|PDB:5DXU}.
FT   STRAND      754    756       {ECO:0000244|PDB:5M6U}.
FT   STRAND      759    764       {ECO:0000244|PDB:5DXU}.
FT   STRAND      775    782       {ECO:0000244|PDB:5DXU}.
FT   HELIX       785    802       {ECO:0000244|PDB:5DXU}.
FT   TURN        803    805       {ECO:0000244|PDB:5DXU}.
FT   STRAND      815    819       {ECO:0000244|PDB:5DXU}.
FT   STRAND      822    826       {ECO:0000244|PDB:5DXU}.
FT   STRAND      829    833       {ECO:0000244|PDB:5DXU}.
FT   HELIX       834    839       {ECO:0000244|PDB:5DXU}.
FT   HELIX       854    862       {ECO:0000244|PDB:5DXU}.
FT   HELIX       865    867       {ECO:0000244|PDB:5DXU}.
FT   HELIX       868    888       {ECO:0000244|PDB:5DXU}.
FT   STRAND      898    902       {ECO:0000244|PDB:5DXU}.
FT   STRAND      907    909       {ECO:0000244|PDB:5DXU}.
FT   HELIX       936    942       {ECO:0000244|PDB:5DXU}.
FT   TURN        943    945       {ECO:0000244|PDB:5DXU}.
FT   HELIX       950    969       {ECO:0000244|PDB:5DXU}.
FT   HELIX       971    981       {ECO:0000244|PDB:5DXU}.
FT   HELIX       982    984       {ECO:0000244|PDB:5DXU}.
FT   HELIX       992   1001       {ECO:0000244|PDB:5DXU}.
FT   TURN       1002   1005       {ECO:0000244|PDB:5DXU}.
FT   HELIX      1008   1030       {ECO:0000244|PDB:5DXU}.
SQ   SEQUENCE   1044 AA;  119479 MW;  A38B5D1A1081A3D0 CRC64;
     MPPGVDCPME FWTKEENQSV VVDFLLPTGV YLNFPVSRNA NLSTIKQLLW HRAQYEPLFH
     MLSGPEAYVF TCINQTAEQQ ELEDEQRRLC DVQPFLPVLR LVAREGDRVK KLINSQISLL
     IGKGLHEFDS LCDPEVNDFR AKMCQFCEEA AARRQQLGWE AWLQYSFPLQ LEPSAQTWGP
     GTLRLPNRAL LVNVKFEGSE ESFTFQVSTK DVPLALMACA LRKKATVFRQ PLVEQPEDYT
     LQVNGRHEYL YGSYPLCQFQ YICSCLHSGL TPHLTMVHSS SILAMRDEQS NPAPQVQKPR
     AKPPPIPAKK PSSVSLWSLE QPFRIELIQG SKVNADERMK LVVQAGLFHG NEMLCKTVSS
     SEVSVCSEPV WKQRLEFDIN ICDLPRMARL CFALYAVIEK AKKARSTKKK SKKADCPIAW
     ANLMLFDYKD QLKTGERCLY MWPSVPDEKG ELLNPTGTVR SNPNTDSAAA LLICLPEVAP
     HPVYYPALEK ILELGRHSEC VHVTEEEQLQ LREILERRGS GELYEHEKDL VWKLRHEVQE
     HFPEALARLL LVTKWNKHED VAQMLYLLCS WPELPVLSAL ELLDFSFPDC HVGSFAIKSL
     RKLTDDELFQ YLLQLVQVLK YESYLDCELT KFLLDRALAN RKIGHFLFWH LRSEMHVPSV
     ALRFGLILEA YCRGSTHHMK VLMKQGEALS KLKALNDFVK LSSQKTPKPQ TKELMHLCMR
     QEAYLEALSH LQSPLDPSTL LAEVCVEQCT FMDSKMKPLW IMYSNEEAGS GGSVGIIFKN
     GDDLRQDMLT LQMIQLMDVL WKQEGLDLRM TPYGCLPTGD RTGLIEVVLR SDTIANIQLN
     KSNMAATAAF NKDALLNWLK SKNPGEALDR AIEEFTLSCA GYCVATYVLG IGDRHSDNIM
     IRESGQLFHI DFGHFLGNFK TKFGINRERV PFILTYDFVH VIQQGKTNNS EKFERFRGYC
     ERAYTILRRH GLLFLHLFAL MRAAGLPELS CSKDIQYLKD SLALGKTEEE ALKHFRVKFN
     EALRESWKTK VNWLAHNVSK DNRQ
//
